Skip to main content

Alexandra Stefanovic

Associate Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Box 3961 Med Ctr, Durham, NC 27710
Hematologic Malignancies, Suite 5000, Durham, NC 27705

Selected Publications


Cutaneous Vasculopathy and Recalcitrant Lower-Extremity Ulcerations

Journal Article Annals of Internal Medicine Clinical Cases · April 1, 2023 Lower-extremity ulcerations are a frequent cause of hospitalization, and those that persist despite appropriate treatment warrant careful scrutiny. We present a case of chronic, progressive leg ulcerations in a young woman accompanied by oral and genital u ... Full text Cite

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

Journal Article Blood Adv · April 12, 2022 Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which be ... Full text Link to item Cite

Acquired angioedema in B cell lymphoproliferative disease: A retrospective case series.

Journal Article Clin Exp Immunol · December 2021 Acquired angioedema due to C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is rare and is associated with underlying lymphoproliferative diseases. C1-INH deficiency may be due to neoplastic over-consumption of C1-INH and the generation of anti-C1-INH autoant ... Full text Link to item Cite

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · November 2021 Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal m ... Full text Link to item Cite

Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

Conference Blood · November 5, 2020 Introduction: There is no standard induction therapy in extranodal marginal zone lymphoma (EMZL); current guidelines borrow from follicular lymphoma, where bendamustine and rituximab (BR) is an accepted standard. The data on BR in EMZL is limited ( ... Full text Cite

Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.

Journal Article Am J Hematol · June 2020 Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown to improve clinical ... Full text Link to item Cite

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?

Journal Article Adv Radiat Oncol · 2019 PURPOSE: This study aimed to evaluate whether higher doses of consolidation radiation therapy (RT), which have been traditionally recommended for osseous sites in diffuse large B-cell lymphoma (DLBCL), are still necessary. METHODS AND MATERIALS: Patients w ... Full text Link to item Cite

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Journal Article Clin Cancer Res · December 15, 2018 PURPOSE: The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended phase I ... Full text Link to item Cite

Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy.

Journal Article Leuk Lymphoma · September 2018 Post-transplant lymphoproliferative disorder (PTLD) develops in 1-3% of liver transplant recipients and no consensus exists about therapeutic management. From 2006 to 2016, 1489 liver transplants were performed at our institution with 20 patients (incidenc ... Full text Link to item Cite

The potential role of complements in cocaine-induced thrombotic microangiopathy.

Journal Article Clin Kidney J · February 2018 Thrombotic microangiopathy (TMA) is a rare disorder characterized by microvascular injury and occlusion resulting in tissue ischemia and dysfunction. TMA occurs in a variety of settings including cocaine use. Although cocaine is widely used in the United S ... Full text Open Access Link to item Cite

Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.

Journal Article Am J Hematol · June 2015 A phase II trial of R-MACLO-IVAM followed by thalidomide maintenance for mantle cell lymphoma (MCL) demonstrated promising progression-free survival (PFS) and overall survival (OS) rates. Thalidomide maintenance was associated with significant toxicity and ... Full text Link to item Cite

Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.

Journal Article Leuk Lymphoma · June 2015 The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with (90)yttrium ((90)Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102) ... Full text Link to item Cite

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Conference Blood · November 15, 2013 AbstractBackgroundThere is ample data for the response rates and clinical outcomes for patients with newly diagnosed multiple myeloma ... Full text Cite

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Conference Blood · November 15, 2013 AbstractBackgroundAmplification and/or over-expression of the mitotic Aurora A kinase (AAK) have been reported in a variety of tumors. ... Full text Cite

Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

Conference Blood · November 16, 2012 AbstractAbstract 1622Background:Contemporary therapy for mantle cell lymphoma (MCL) in fit patients u ... Full text Cite

Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.

Journal Article Am J Ther · July 2012 Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated activity in renal cell carcinoma and is now widely used in the palliative treatment of patients with metastatic renal cell carcinoma. It is generally well tolerated bu ... Full text Link to item Cite

Cutaneous Vasculopathy and Recalcitrant Lower-Extremity Ulcerations

Journal Article Annals of Internal Medicine Clinical Cases · April 1, 2023 Lower-extremity ulcerations are a frequent cause of hospitalization, and those that persist despite appropriate treatment warrant careful scrutiny. We present a case of chronic, progressive leg ulcerations in a young woman accompanied by oral and genital u ... Full text Cite

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

Journal Article Blood Adv · April 12, 2022 Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which be ... Full text Link to item Cite

Acquired angioedema in B cell lymphoproliferative disease: A retrospective case series.

Journal Article Clin Exp Immunol · December 2021 Acquired angioedema due to C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is rare and is associated with underlying lymphoproliferative diseases. C1-INH deficiency may be due to neoplastic over-consumption of C1-INH and the generation of anti-C1-INH autoant ... Full text Link to item Cite

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · November 2021 Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal m ... Full text Link to item Cite

Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

Conference Blood · November 5, 2020 Introduction: There is no standard induction therapy in extranodal marginal zone lymphoma (EMZL); current guidelines borrow from follicular lymphoma, where bendamustine and rituximab (BR) is an accepted standard. The data on BR in EMZL is limited ( ... Full text Cite

Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.

Journal Article Am J Hematol · June 2020 Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown to improve clinical ... Full text Link to item Cite

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?

Journal Article Adv Radiat Oncol · 2019 PURPOSE: This study aimed to evaluate whether higher doses of consolidation radiation therapy (RT), which have been traditionally recommended for osseous sites in diffuse large B-cell lymphoma (DLBCL), are still necessary. METHODS AND MATERIALS: Patients w ... Full text Link to item Cite

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Journal Article Clin Cancer Res · December 15, 2018 PURPOSE: The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended phase I ... Full text Link to item Cite

Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy.

Journal Article Leuk Lymphoma · September 2018 Post-transplant lymphoproliferative disorder (PTLD) develops in 1-3% of liver transplant recipients and no consensus exists about therapeutic management. From 2006 to 2016, 1489 liver transplants were performed at our institution with 20 patients (incidenc ... Full text Link to item Cite

The potential role of complements in cocaine-induced thrombotic microangiopathy.

Journal Article Clin Kidney J · February 2018 Thrombotic microangiopathy (TMA) is a rare disorder characterized by microvascular injury and occlusion resulting in tissue ischemia and dysfunction. TMA occurs in a variety of settings including cocaine use. Although cocaine is widely used in the United S ... Full text Open Access Link to item Cite

Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.

Journal Article Am J Hematol · June 2015 A phase II trial of R-MACLO-IVAM followed by thalidomide maintenance for mantle cell lymphoma (MCL) demonstrated promising progression-free survival (PFS) and overall survival (OS) rates. Thalidomide maintenance was associated with significant toxicity and ... Full text Link to item Cite

Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.

Journal Article Leuk Lymphoma · June 2015 The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with (90)yttrium ((90)Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102) ... Full text Link to item Cite

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Conference Blood · November 15, 2013 AbstractBackgroundThere is ample data for the response rates and clinical outcomes for patients with newly diagnosed multiple myeloma ... Full text Cite

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Conference Blood · November 15, 2013 AbstractBackgroundAmplification and/or over-expression of the mitotic Aurora A kinase (AAK) have been reported in a variety of tumors. ... Full text Cite

Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

Conference Blood · November 16, 2012 AbstractAbstract 1622Background:Contemporary therapy for mantle cell lymphoma (MCL) in fit patients u ... Full text Cite

Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.

Journal Article Am J Ther · July 2012 Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated activity in renal cell carcinoma and is now widely used in the palliative treatment of patients with metastatic renal cell carcinoma. It is generally well tolerated bu ... Full text Link to item Cite

Post-transplant lymphoproliferative disorder presented as small bowel intussusception in adult liver transplant patient.

Journal Article J Korean Surg Soc · January 2012 Intestinal obstruction after liver transplant is a rare complication, with diverse clinical manifestations. Intestinal adhesion is the most common cause. However, internal hernia, abdominal wall hernia, and neoplasm are also reported. Intussusception is an ... Full text Open Access Link to item Cite

A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment.

Journal Article Am J Ther · September 2011 Thrombotic thrombocytopenia purpura (TTP) is a severe multisystem disorder characterized by fever, microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, and impaired renal function. Platelet counts are usually diminished, whereas the bo ... Full text Link to item Cite

Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Journal Article Br J Haematol · January 2011 Extranodal marginal zone B-cell lymphoma is the most common orbital tumour. We conducted a retrospective analysis to examine: (i) the impact of initial presentation and staging on outcome and (ii) response to various treatment modalities and the effect of ... Full text Link to item Cite

Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors.

Journal Article J Neurooncol · January 2011 Primary central nervous system lymphoma (PCNSL) accounts for approximately 4% of all primary brain tumors and has a poor prognosis in both immunocompetent as well as in immunocompromised patients. We conducted a retrospective analysis to examine the clinic ... Full text Link to item Cite

Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.

Journal Article Am J Clin Pathol · November 2010 Plasmablastic lymphoma (PBL), initially characterized as an aggressive lymphoma arising in the jaw and oral mucosa in HIV-infected patients, was recently reported to occur with extraoral manifestations, heterogeneous histologic findings, and variable assoc ... Full text Link to item Cite

Central nervous system manifestations of marginal zone B-cell lymphoma.

Journal Article Ann Hematol · October 2010 Primary or secondary central nervous system (CNS) involvement by marginal zone B-cell lymphoma (MZBCL) is rare. A retrospective analysis of patients was done with MZBCL involving the CNS, diagnosed and treated at our institution between 2004 and 2010. We i ... Full text Link to item Cite

Rare PTCLs: treatment lagging behind pathobiologic advances.

Journal Article Oncology (Williston Park) · January 2010 Link to item Cite

Extranodal marginal zone lymphoma of the ocular adnexa.

Journal Article Blood · July 16, 2009 Lymphomas of the ocular adnexa are a heterogeneous group of malignancies, composing approximately 1% to 2% of non-Hodgkin lymphomas (NHLs) and 8% of extranodal lymphomas. The most common subtype, accounting for up to 80% of cases of primary ocular adnexal ... Full text Link to item Cite

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.

Journal Article Bone Marrow Transplant · July 2009 High-dose chemotherapy with autologous SCT has become standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). To improve safety and efficacy of this treatment, new conditioning regimens are being developed. We retrospectively r ... Full text Link to item Cite

[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.

Journal Article Leuk Lymphoma · June 2009 Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in the treatment of B-cell non-Hodgkin lymphomas (NHL). Most adverse effects are due to infusion-related reactions, and severe respiratory complications are rare. We retrospectively reviewed ... Full text Link to item Cite

Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database.

Journal Article Leuk Lymphoma · July 2008 Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review ... Full text Link to item Cite

Visualization of carbohydrate-binding molecules expressed by myelomono- and erythropoietic cells derived from human bone marrow: an immunoenzymatic double-staining study.

Journal Article Histochem J · January 2000 Interactions between human haematopoietic and bone marrow stromal cells are governed by complex carbohydrate-mediated adhesion processes. In order to evaluate corresponding carbohydrate-binding sites on human myelo- and erythropoietic cells which were able ... Full text Link to item Cite

Enrichment of human bone marrow mononuclear phagocytes and characterization of macrophage subpopulations by immunoenzymatic double staining.

Journal Article Histochem J · April 1998 In order to isolate and enrich bone marrow mononuclear phagocytes, we performed magnetic-activated cell sorting using beads coupled to a monoclonal antibody directed against the monocyte/macrophage surface molecule CD14. Colocalization of antigens in singl ... Full text Link to item Cite